Nebius Group N.V. (NBIS) vs United Therapeutics Corporation (UTHR)
A side-by-side comparison of Nebius Group N.V. and United Therapeutics Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of July 28, 2026. Differences are shown without an overall score or investment verdict.
Different business models: NBIS is classified in Technology; UTHR is classified in Healthcare. Margin, capital intensity, and valuation differences should be interpreted in that sector context.
NBIS
Nebius Group N.V.
$169.69TechnologyDelayed quote: Jul 28, 2026, 4:00 PM EDT
UTHR
United Therapeutics Corporation
$523.63HealthcareDelayed quote: Jul 28, 2026, 4:00 PM EDT
Total return — NBIS vs UTHR
growth of $100 · dividends reinvested · last 2yNBIS +839.4%UTHR +42.5%NBIS compounded faster
Log scale — wide-divergence pair
NBIS UTHR
NBIS vs UTHR: by the numbers
- •NBIS is the larger company ($40.73B vs $22.23B market cap).
- •UTHR trades at the lower trailing earnings multiple (19.52 vs 62.63 P/E), one valuation lens rather than an overall verdict.
- •NBIS converts more revenue to profit (95.27% vs 40.61% net margin).
- •UTHR grew revenue faster over the past five years (16.05% vs -23.11% CAGR).
Metrics side by side
Valuation
| Metric | NBIS | UTHR |
|---|---|---|
| P/E ratio | 62.63 | 19.52 |
| Forward P/E | N/A | 18.94 |
| P/S ratio | 66.12 | 7.86 |
| P/B ratio | 8.02 | 4.22 |
| PEG ratio | N/A | 1.16 |
| EV / EBITDA | N/A | 15.63 |
| FCF yield | N/A | 4.08% |
Profitability
| Metric | NBIS | UTHR |
|---|---|---|
| Gross margin | 68.63% | 86.58% |
| Operating margin | -112.53% | 45.34% |
| Net margin | 95.27% | 40.61% |
| ROE | 11.55% | 21.82% |
| ROIC | -4.75% | 16.13% |
Growth (annualized)
| Metric | NBIS | UTHR |
|---|---|---|
| Revenue CAGR (5Y) | -23.11% | 16.05% |
| EPS CAGR (5Y) | -35.43% | 20.93% |
| FCF CAGR (5Y) | N/A | 12.12% |
| Total return CAGR (5Y) | N/A | 23.16% |
Frequently asked
- Which has the lower trailing P/E, NBIS or UTHR?
- UTHR has the lower trailing P/E: NBIS trades at 62.63 and UTHR at 19.52. P/E is one valuation measure and does not by itself establish which business is cheaper.
- Which has grown faster, NBIS or UTHR?
- Over the past five years, UTHR grew revenue faster — NBIS at a -23.11% CAGR versus UTHR at 16.05%.
- Is NBIS or UTHR more profitable?
- NBIS runs the higher net margin — NBIS at 95.27% versus UTHR at 40.61%.
Go deeper
Dig into the metrics
Nebius P/E ratioUnited Therapeutics P/E ratioNebius dividend yieldUnited Therapeutics dividend yieldNebius ROEUnited Therapeutics ROENebius operating marginUnited Therapeutics operating marginNebius revenue growthUnited Therapeutics revenue growthNebius free cash flowUnited Therapeutics free cash flow
Nebius & United Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified July 28, 2026.